Return
Biography
Prof. Matti Osmo Antero Lehtinen
Prof. Matti Osmo Antero Lehtinen
University of Tampere, School of Health Sciences, Finland
 
E-mail: matti.lehtinen@uta.fi
 
Qualifications
 
Professorship qualification: virology (-90), epidemiol.(-04), public health (-10), University of Tampere
1995 Docent (adjunct professor) in virology, University of Oulu
1987 Docent (adjunct professor) in virology, University of Tampere
1985 M.D., Ph.D., (University of Tampere)
1983 M.D., (University of Tampere)
 
Publications (Selected)
  1. Lehtinen M, Dillner J, Knekt P, Luostarinen T, Aromaa A, Kirnbauer R, Koskela P, Paavonen J, Peto R, Schiller JT, Hakama M: Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study.  BMJ 312:537-539, 1996.
  2. Lehtinen T, Luostarinen T, Dillner J, Aromaa A, Hakama M, Hakulinen T, Knekt P, Leinikki P, Lumio J, Lähdeaho M-L, Maatela J, Teppo L, Lehtinen M: Serum p53 accumulation and altered antibody responses to Epstein-Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Br J Haematol, 93(1):104-110, 1996.
  3. Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Abeler V, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller JT, Hakulinen T, Thoresen S, Hakama M: A prospective seroepidemiological study of human papillomavirus infection as arisk factor for invasive cervical cancer. J Natl Cancer Inst 89:1293-1299, 1997.
  4. Luostarinen T, Geijerstamm V, Bjorge T, Eklund C, Hakama M, Hakulinen T, Jellum E, Koskela P, Paavonen J, Pukkala E, Schiller JT, Thoresen S, Youngman L, Dillner J, Lehtinen M: No excess risk of cervical carcinoma in women seropositive for both HPV16 and HPV6/11. Int J Cancer 80:818-822, 1999.
  5. Mork J, Lie A-K, Glattre E, Clark S, Hallmans G, Jellum E, Koskela P, Moller B, Pukkala E, Schiller JT, Wang Z, Youngman L, Lehtinen M, Dillner J: Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. New Engl J Med 344 (1):1125-1131, 2001. 
  6. Lehtinen M, Koskela P, Ögmundsdottir H, Bloigu A, Dillner J, Gudnadottir M, Hakulinen T, Kvarnung M, Pukkala E, Tulinius H, Lehtinen T. Maternal herpesvirus infections and risk of acute lymphoblastic leukemia in the offspring. Am J Epidemiol 158 (3):207-213, 2003.
  7. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3:e138, 2006.
  8. Lehtinen M, Kaasila M, Pasanen K, Patama T, Palmroth J, Laukkanen P, Pukkala E, Koskela P. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 119:2612-2619, 2006.
  9. Tedeschi RM, Bloigu A, Ögmundsdottir H, Dillner J, de Paoli P, Gudnadottir M, Koskela P, Pukkala E, Lehtinen T, Lehtinen M. Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. Am J Epidemiol 165:134-137, 2007
  10. Villa L, Perez G, Kjaer S, Paavonen J, Lehtinen M, Munoz N, Sigurdsson K, Hernandez-Avila M, Skjeldestad FE, Thoresen S, Garcia P, Majewski S, Dillner J, Olsson S-E, Eng HT, Bosch FX, Ault KA, Brown DR, Ferris DG, Koutsky LA, Kurman RJ, Myers ER, Barr E, Boslego J, Bryan J, Esser MT, Gause CK, Hesley TM, Lupinacci LC, Sings HL, Taddeo FJ, Thornton AR. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. New Engl J Med 356:1915-1927, 2007.
  11. Villa L, Perez G, Kjaer S, Lehtinen M, Paavonen J, Muñoz, N, Sigurdsson, K, Hernandez-Avila, M, Skjeldestad FE, Thoresen S, García P, Majewski S, Dillner J, Olsson S-E, Eng HT, Bosch FX, Ault KA, Brown DR, Ferris DG, Koutsky LA, Kurman RJ, Myers ER, Barr E, Boslego J, Bryan J, Esser MT, Gause CK, Hesley TM, Lupinacci LC, Sings HL, Taddeo FJ, Thornton AR. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861-1868, 2007.
  12. Leppik L, Gunst K, Lehtinen M, Dillner J, Streker K, deVilliers EM. In vivo and in vitro intragenomic rearrangement of TT viruses. J Virol 81:9346-9356, 2007.
  13. Siemen Kapeu A, Youngman L, Jellum E, Dillner J, Hakama M, Koskela P, Lenner P, Lowe A, Luostarinen T, Mahlamäki E, Thoresen S, Wadell G, Ögmundsdottir H, Lehtinen M. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol 169:480-488, 2009.
  14. PaavonenJ, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR0, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki F, Schwarz TF, Poppe WAJ, Bosch XF, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.Lancet 374:301-314, 2009.
  15. Tedeschi R, Bzhalava D, Luostarinen T, Lehtinen M, Lowe A, Surcel HM, Ögmundsdottir H, Lehtinen T. No risk of maternal EBV infection for childhood leukemia. Cancer Epidemiol Biomarkers Prev 18: 2790- 2792, 2009
  16. Merikukka M, Kaasila M, Palmroth J, Koskela P, Kirnbauer R, Paavonen J, Pukkala E, Surcel H-M, Lehtinen M. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int J Cancer 128:1114-1119, 2011.
  17. Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer, Epub 2011.
  18. LehtinenM, PaavonenJ, WheelerCM, JaisamrarnU, Garland S, NaudP, Salmerón J, ChowS-N, ApterD, Kitchener H, CastellsaguéX, Teixeira1 JC, SkinnerRS, HedrickJ, LimsonG, SzarewskiA, RomanowskiB, AokiFY, SchwarzTF, PoppeWAJ, BoschXF, de CarvalhoN, GermarMJ, PetersK, DavidMP, DescampsD, F Struyf, DubinG. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, in press
  19. Wheeler CM, Castellsague X, Garland S, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow S-N, Apter D, Kitchener H, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki F, Schwarz TF, Poppe WAJ, Bosch XF, Mindel A, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, in press.
  20. Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, Smith P. Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24:233-241, 2006.